These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37812367)

  • 1. Mechanisms Behind NAFLD: a System Genetics Perspective.
    Pourteymour S; Drevon CA; Dalen KT; Norheim FA
    Curr Atheroscler Rep; 2023 Nov; 25(11):869-878. PubMed ID: 37812367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Baek JH; Kim MS; Jung HR; Hwang MS; Lee CH; Han DH; Lee YH; Yi EC; Im SS; Hwang I; Kim K; Chung JY; Chun KH
    Exp Mol Med; 2023 Jul; 55(7):1520-1530. PubMed ID: 37394587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression.
    Azzu V; Vacca M; Kamzolas I; Hall Z; Leslie J; Carobbio S; Virtue S; Davies SE; Lukasik A; Dale M; Bohlooly-Y M; Acharjee A; Lindén D; Bidault G; Petsalaki E; Griffin JL; Oakley F; Allison MED; Vidal-Puig A
    Mol Metab; 2021 Jun; 48():101210. PubMed ID: 33722690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    Govaere O; Petersen SK; Martinez-Lopez N; Wouters J; Van Haele M; Mancina RM; Jamialahmadi O; Bilkei-Gorzo O; Lassen PB; Darlay R; Peltier J; Palmer JM; Younes R; Tiniakos D; Aithal GP; Allison M; Vacca M; Göransson M; Berlinguer-Palmini R; Clark JE; Drinnan MJ; Yki-Järvinen H; Dufour JF; Ekstedt M; Francque S; Petta S; Bugianesi E; Schattenberg JM; Day CP; Cordell HJ; Topal B; Clément K; Romeo S; Ratziu V; Roskams T; Daly AK; Anstee QM; Trost M; Härtlova A
    J Hepatol; 2022 May; 76(5):1001-1012. PubMed ID: 34942286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.
    Dongiovanni P; Romeo S; Valenti L
    Biomed Res Int; 2015; 2015():460190. PubMed ID: 26273621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.